Novartis has been flying pretty high lately, despite delays and bad news about a major diabetes drug it hopes to launch next spring. The Swiss drug giant's 2005 income of $6.1 billion on sales of $32.2 billion set a record that CEO Daniel Vasella expects will be broken this year. He spoke with TIME's UNMESH KHER and BILL SAPORITO about vaccines, Democrats and why the firm is wading into China.
You expect another year of record earnings?
I think it will be a good year. We currently have five filings that are waiting [for approval], and that will create some pressure, accentuate...
To continue reading:
or
Log-In
